Sign inJoin waitlistJoin the waitlist

Warren Fingrut

Assistant Professor of Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

SCB Cancer Research Training and Education Coordination Liaison · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Sloan Kettering Institute
2022–2023
Memorial Sloan Kettering Cancer Center
2020–2022
University of British Columbia
2018–2020
University of Toronto
2015–2018
University of British Columbia Faculty of Medicine
2011–2015

Research

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy
Journal of Clinical Oncology · 2022 · 133 citations
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
Leukemia · 2023 · 86 citations
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis
Blood · 2022 · 80 citations

Juliet Barker
12 papers
AS
Andromachi Scaradavou
9 papers
Elizabeth Shpall
7 papers
MP
Miguel-Angel Perales
7 papers
Partow Kebriaei
7 papers
IP
Ioannis Politikos
6 papers
Portia Smallbone
6 papers · 6 as a fellow
Richard Champlin
6 papers
SG
Sergio Giralt
6 papers
AO
Amanda Olson
5 papers
Betul Oran
5 papers
BS
Brian Shaffer
5 papers

Clinical trials

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2029
Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health
Principal investigator · Recruiting
M.D. Anderson Cancer Center
2024–2029
Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
Principal investigator · Recruiting
M.D. Anderson Cancer Center
2024–2029
Personalized NK Cell Therapy in CBT
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2016–2027